Physician

Philip Louis Marjon, M.D.

According to 2025 Medicare claims, Philip Marjon, M.D. (NPI: 1912234121) practices hematology/oncology in the San Diego-Chula Vista-Carlsbad, CA market, with the plurality of this provider's patient population coming from San Diego, CA. This provider's primary affiliated billing organization is CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (NPI: 1083661607; TIN: 770324589) and primary practice location at 92069-3599.

Marjon's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 447 traditional Medicare patients, billed 107,587 HCPCS/CPT codes, and received $2,215,203 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 531 prescription claims across 200 beneficiaries totaling $1,764,706 in drug costs, led by Brukinsa (Zanubrutinib). 2020 DME data shows 52 claims. Open Payments data shows 227 records totaling $6,240. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $329,865 to $2,215,203. Similarly, Part D prescription costs have risen steadily, from $336,115 to $1,764,706. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	333	19,623	$329,865
2016	401	5,472	$139,113
2017	298	1,042	$50,370
2018	295	1,057	$49,804
2019	314	1,157	$55,524
2020	312	1,168	$67,628
2021	317	909	$74,345
2022	37	3,648	$119,417
2023	61	8,411	$274,766
2024	447	107,587	$2,215,203

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	77	498	$336,115
2016	119	596	$454,404
2017	140	1,022	$1,372,136
2018	169	1,411	$1,513,074
2019	195	1,248	$1,263,610
2020	203	1,489	$1,472,122
2021	238	1,493	$1,994,883
2022	206	793	$1,292,730
2023	202	962	$1,857,535
2024	200	531	$1,764,706

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	11	$11,304
2018	N/R	11	$139
2019	N/R	26	$3,510
2020	N/R	52	$3,512
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	77	183	$117
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	249	391	$107
96372	Injection of drug or substance under skin or into muscle	104	250	$12
36415	Insertion of needle into vein for collection of blood sample	128	260	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	104	278	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	17	510	$251,610
Promacta	Eltrombopag Olamine	17	510	$234,266
Letrozole	Letrozole	111	7,623	$3,005
Hydroxyurea	Hydroxyurea	46	2,715	$1,399
Ondansetron Odt	Ondansetron	17	400	$471

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	227	$6,240	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Philip Louis Marjon, M.D.?

Tedicare shows public-source Medicare data for Philip Louis Marjon, M.D. (NPI 1912234121), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Philip Louis Marjon, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Philip Louis Marjon, M.D.?

Philip Louis Marjon, M.D. is linked to CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (billing NPI 1083661607) in the available physician profile data.

Does Philip Louis Marjon, M.D. have Open Payments data?

Philip Louis Marjon, M.D. has 227 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.